Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) -- AVPR2 gain-of-function (constitutively-active vasopressin V2 receptor; e.g. R137C/R137L, F229V, I130N) OMIM 300539
In Nephrogenic syndrome of inappropriate antidiuresis (AVPR2, OMIM 300539), the master switch sits on the ↑ UP branch ([F] forced below); the healthy state is the OFF well. The forced corrective direction is to lower s toward OFF branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5342, γ 1.4618, spinodal 0.6803). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for Nephrogenic syndrome of inappropriate antidiuresis is an R19 double-well emerged from the real proximal-promoter DNA of AVPR2. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
emergent axis
↑ UP [F]
healthy branch
OFF
lesion
GOF
γ (stiffness)
1.4618
barrier
0.5342
spinodal
0.6803
s_on / s_off
1.2090 / -1.2090
fragility
0.29
corrective polarity
clear
forced direction
lower s toward OFF branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.5342 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: lower s toward OFF branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If clearing/opposing the accumulating AVPR2 does NOT relieve the disease branch in a AVPR2 model, the h-restore(clear) lever is refuted for this axis.
EXCLUDED: gain-of-function -- the lesion is not a destabilised healthy product to stiffen; the corrective move is to clear/oppose the toxic drive (h-restore)
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual AVPR2 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.
Agents mapped onto the lever
✓ Agreement with established practice. The corrective direction derived here (lower s toward OFF branch) independently matches an agent already in clinical use for this disease: V2R inverse-agonist vaptan (tolvaptan; conivaptan). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
Rho-kinase (ROCK) pathway restraint (investigational; mechanistic, not a developed therapy)
Ranieri 2020 Cells 9:1354 (R137L V2R signals via ROCK; ROCK inhibitor lowers pT269-AQP2)
decrease
investigational
2
◇ in trials
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Direction-only candidate leads (corpus join)
Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.
Mechanism. An approved, safety-characterised V2 receptor (AVPR2) inverse agonist that opposes constitutive V2 signalling. Direction on the disease axis: decrease -- oppose the gain-of-function receptor drive in nephrogenic syndrome of inappropriate antidiuresis (NSIAD). Engaged node: AVPR2 (shared with X-linked nephrogenic diabetes insipidus, which is a LOF node deriving the OPPOSITE direction; the sign filter isolates tolvaptan to the GOF NSIAD node only). Allele scope: applies to the vaptan-SENSITIVE activating variants (e.g. F229V, I130N); the most common NSIAD variants R137C/R137L are vaptan-RESISTANT (they drive an alternative arrestin/Rho-kinase pathway), so this is a partial, subset-scoped direction match -- a direction statement, not an efficacy claim. NOVEL off-label direction-only hypothesis for NSIAD (no efficacy/approval/availability claim); confirm current evidence.
Prior-art. Direction-only hypothesis: the geometry derives a decrease (oppose the gain-of-function receptor drive) for the AVPR2 GOF node; tolvaptan, an approved V2 receptor inverse agonist, opposes constitutive V2 signalling -- a matched decrease, gene-specific to AVPR2. SUBSET-SCOPED: applies to vaptan-sensitive activating variants (e.g. F229V, I130N); the most common R137C/R137L variants are vaptan-resistant. The sign filter isolates this from the AVPR2 LOF X-linked nephrogenic diabetes insipidus node, which derives the opposite direction. Off-label/investigational for NSIAD; confirm current evidence. No efficacy/availability claim.
Safety (qualitative; no magnitude). approved vaptan (other indications include hyponatraemia/SIADH and ADPKD); hepatic-monitoring considerations per label (qualitative; no magnitude); in NSIAD it applies only to vaptan-SENSITIVE activating AVPR2 variants -- the most common R137C/R137L variants are vaptan-RESISTANT; confirm current evidence
Falsifier. If tolvaptan (a gene-specific decrease agent) clearing/opposing the accumulating load does NOT relieve the UP [F] disease branch in a AVPR2 model, the h-restore(clear) direction is refuted for tolvaptan here.
Source: Tolvaptan, approved V2 receptor (AVPR2) inverse agonist; NSIAD vaptan-sensitivity literature (vaptan-resistant R137C/R137L vs vaptan-sensitive F229V/I130N)
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Evidence & provenance
What is reproduced vs. cited for this page.
element
grade
basis
R19 switch & cusp geometry (this page)
[V] verified
emerged from measured promoter γ of AVPR2; deterministic, 2×sha256 identical
corrective direction
[F] forced
forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads
[O] open
direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).